EMERA007 - An Open Label, Active-treatment Controlled, Phase 2a Pilot Study to Explore Safety and Efficacy of NBMI Treatment in Patients With Beta Thalassemia Major, Requiring Iron Chelation
Latest Information Update: 04 Nov 2021
At a glance
- Drugs Emeramide (Primary)
- Indications Beta-thalassaemia
- Focus Adverse reactions
- Acronyms EMERA007
- Sponsors EmeraMed Limited
- 20 Aug 2021 Status changed from recruiting to completed.
- 28 Nov 2019 Status changed from not yet recruiting to recruiting.
- 18 Sep 2019 New trial record